The US Food and Drug Administration has updated two key guidance documents that significantly ease regulatory oversight of general wellness devices and certain types of clinical decision support (CDS) software. The changes signal a notable shift in FDA’s approach to digital health and artificial intelligence–enabled products, emphasizing flexibility and market predictability while maintaining oversight of medical-grade technologies.
FDA stated that the updates are intended to promote innovation and support faster adoption of digital health tools without compromising patient safety.
A Shift Toward Regulatory Flexibility
The updated guidances narrow the scope of products subject to FDA oversight or premarket authorization. FDA emphasized that products not marketed as medical-grade and not intended to diagnose, treat, or prevent disease should generally fall outside traditional device regulation.
This policy shift reflects FDA’s acknowledgment that many AI-enabled and software-based technologies evolve rapidly and may not fit well within traditional regulatory models designed for static medical devices.
Changes to Clinical Decision Support Oversight
FDA revised its approach to CDS software by refining how it interprets automation bias. Earlier guidance raised concerns that software providing a single recommendation could lead healthcare professionals to over-rely on automated outputs, potentially increasing the risk of medical errors.
Under the updated guidance, FDA clarified that CDS software providing a single clinically appropriate recommendation may qualify for enforcement discretion, provided it meets established exemption criteria. These include ensuring that healthcare professionals can independently review the basis for the recommendation and that the software does not replace clinical judgment.
FDA also added clearer examples illustrating when CDS software is exempt from regulation and when it would still be considered a medical device, offering developers greater predictability.
Expanded Definition of General Wellness Products
FDA also updated its guidance on general wellness products, expanding the types of technologies that may fall outside medical device regulation. The agency clarified that devices using non-invasive sensors to measure physiological parameters, such as blood pressure, heart rate variability, oxygen saturation, or blood glucose, may be considered general wellness products if their outputs are solely intended for wellness purposes.
To qualify, products must not involve risky interventions, must not claim medical or clinical use, and must not substitute for FDA-authorized medical devices. FDA emphasized that claims and marketing language remain a critical factor in determining regulatory status.
The updated guidance also provides additional examples of wearable devices, athlete-focused monitoring tools, and nutrition-related products that may qualify as general wellness products when appropriately positioned.
Implications for Digital Health Developers
These updates provide digital health developers with increased regulatory clarity and flexibility but also place greater responsibility on companies to carefully define intended use and marketing claims. Products that blur the line between wellness and medical use may still trigger regulatory oversight.
For organizations developing AI-enabled software or wearable technologies, early regulatory strategy and careful product positioning will be essential to avoid unintended compliance risks.
How EMMA International Supports Digital Health Strategy
At EMMA International, we help digital health, medical device, and software developers navigate evolving FDA guidance and determine appropriate regulatory pathways. Our teams support intended-use assessments, regulatory classification strategy, CDS exemption analysis, and compliance planning across FDA and global markets.
We work with clients to align product design, claims, and evidence strategies with regulatory expectations, enabling innovation while managing risk.
For more information on how EMMA International can assist, visit www.emmainternational.com or contact us at (248) 987-4497 or info@emmainternational.com.
Reference:
U.S. Food and Drug Administration. Clinical Decision Support Software Guidance. Final update, January 2026.
U.S. Food and Drug Administration. General Wellness: Policy for Low Risk Devices. Final update, January 2026.
Regulatory Affairs Professionals Society. FDA relaxes oversight of general wellness devices, CDS software. January 7, 2026.
